technically, IMGN's a little extended here, I would consider put sales as a lower-risk, lower cost way to enter for defensive investors. On the other hand, IMGN traded $18 last year and approval seems close. Thanks for the MA cross info, keep an eye on the option vol.
Some some tweets from Conference that many believe the delay on approval is over labeling. If Roche is able to negotiate a broader label, analyst will have to revalue IMGN. I see IMGN as a patent extension play for all MAB oncology drugs. Lot's of intrinsic value here that will soon be recognized. IMGN is also a scarcity value in pure MAB market. I'm long after this last UBS short call. This is the transformation from R&D to commercialization long term rise. Don't be left out as an acquisition can occur anytime after first 2 -3 quarters of TDM1 sales. Will be de-risked on approval!